Literature DB >> 23667200

Off-label use of oncology drugs: too much, too little, or just right?

Harold J Burstein.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23667200     DOI： 10.6004/jnccn.2013.0066

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  4 in total

Review 1.  Artificial intelligence unifies knowledge and actions in drug repositioning.

Authors:  Zheng Yin; Stephen T C Wong
Journal:  Emerg Top Life Sci       Date:  2021-12-21

Review 2.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.

Authors:  Guangxu Jin; Stephen T C Wong
Journal:  Drug Discov Today       Date:  2013-11-14       Impact factor: 7.851

3.  Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data.

Authors:  Anne A Eaton; Camelia S Sima; Katherine S Panageas
Journal:  J Natl Compr Canc Netw       Date:  2016-01-05       Impact factor: 11.908

4.  Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.

Authors:  R Kurzrock; L A Gurski; R W Carlson; D S Ettinger; S M Horwitz; S K Kumar; L Million; M von Mehren; A B Benson
Journal:  Ann Oncol       Date:  2019-10-01       Impact factor: 32.976
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.